An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: Impact of multidrug resistance

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Micek, Scott T ^a   Wunderink, Richard G ^b   Kollef, Marin H ^c   Chen, Catherine ^c   Rello, Jordi ^d   Chastre, Jean ^e   Antonelli, Massimo ^f   Welte, Tobias ^g   Clair, Bernard ^h   Ostermann, Helmut ⁱ   Calbo, Esther ^j   Torres, Antoni ^k   Menichetti, Francesco ^l   Schramm, Garrett E ^m   Menon, Vandana ⁿ  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h RAYMOND POINCARÉ HOSPITAL   (France)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j Hospital Universitari Mútua Terrassa   (Spain)

^k Pneumology Department   (Spain)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m MAYO CLINIC   (United States)

ⁿ CUBIST PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGING; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL STRAIN; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISK DIFFUSION; DRUG CHOICE; FEMALE; FRANCE; GERMANY; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; SURVIVAL RATE; UNITED STATES; AGED; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; HOSPITAL MORTALITY; HOSPITALIZATION; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; TRENDS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; MORTALITY; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84930199723     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0926-5     Document Type: Article

References (29)

1. Zilberberg MD, Shorr AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med. 2013;8:559-63.
2. Croughs PD, Li B, Hoogkamp-Korstanje JA, Stobberingh E, Antibiotic Resistance Surveillance Group. Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands. Eur J Clin Microbiol Infect Dis. 2013;32:283-88.
3. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.
4. Nathan C, Cars O. Antibiotic resistance - problems, progress, and prospects. N Engl J Med. 2014;371:1761-3.
5. Kollef MH, Micek ST. Rational Use of Antibiotics in the ICU: Balancing stewardship and clinical outcomes. JAMA. 2014;312:1403-4.
6. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-53.
7. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, Day AG, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008;23:18-26.
8. Crouch Brewer S, Wunderink RG, Jones CB, Leeper Jr KV. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996;109:1019-29.
9. Kollef MH, Chastre J, Clavel M, Restrepo MI, Michiels B, Kaniga K, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012;16:R218.
10. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888-95.
11. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK, Canadian Critical Care Trials Group. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27:322. e7-14.
12. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409-17.
13. Micek ST, Reichley RM, Kollef MH. Health care-associated pneumonia (HCAP): empiric antibiotics targeting methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa predict optimal outcome. Medicine (Baltimore). 2011;90:390-5.
14. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
15. Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47:S3-13.
16. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement 2009; M100-S19. Wayne, PA: CLSI.
17. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Versions 1.3 and 2.0. http://www.eucast.org/clinical_breakpoints/ . Accessed 25 August 2014.
18. Peña C, Gómez-Zorrilla S, Oriol I, Tubau F, Dominguez MA, Pujol M, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis. 2013;32:413-20.
19. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66:401-14.
20. Di Pasquale M, Ferrer M, Esperatti M, Crisafulli E, Giunta V, Li Bassi G, et al. Assessment of Severity of ICU-Acquired Pneumonia and AssociationWith Etiology. Crit Care Med. 2014;42:303-12.
21. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteremia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol. 2014;63:1679-87.
22. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2013;57:1373-83.
23. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188:985-95.
24. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis. 2012;54:193-8.
25. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al. Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia: a European perspective. Thorax. 2013;68:997-9.
26. Burnham CA, Frobel RA, Herrera ML, Wickes BL. Rapid ertapenem susceptibility testing and Klebsiella pneumoniae carbapenemase phenotype detection in Klebsiella pneumoniae isolates by use of automated microscopy of immobilized live bacterial cells. J Clin Microbiol. 2014;52:982-6.
27. Laffler TG, Cummins LL, McClain CM, Quinn CD, Toro MA, Carolan HE, et al. Enhanced diagnostic yields of bacteremia and candidemia in blood specimens by PCR-electrospray ionization mass spectrometry. J Clin Microbiol. 2013;51:3535-41.
28. Beyrouthy R, Robin F, Cougnoux A, Dalmasso G, Darfeuille-Michaud A, Mallat H, et al. Chromosome-mediated OXA-48 carbapenemase in highly virulent Escherichia coli. J Antimicrob Chemother. 2013;68:1558-61.
29. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, et al. Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis. 2015;211:1296-305.